High-dose chemotherapy with autologous stem cell support in an adult with bone marrow relapse of medulloblastoma Millot et al 1 recently reported the effectiveness of treatment strategies including chemotherapy with etoposide and carboplatin followed by high-dose chemotherapy with peripheral blood stem cell transplantation in two adults with recurrent extraneuronal medulloblastoma (patients still in complete remission 20 and 27 months after treatment). We describe a case of an adult with medulloblastoma treated with the same regimen for bone and bone marrow metastasis involvement.
In 1996, a 33-year-old man received surgery and craniospinal irradiation for a localized cerebellar medulloblastoma. Thirty-six months later, in April 1999, he developed a pancytopenia due to bone marrow involvement, and bone metastases, without relapse in the central nervous system. Etopside 100 mg/m 2 once daily i.v. and carboplatin 160 mg/m 2 once daily i.v. for 5 consecutive days, every 4 weeks, resulted in a complete clinical and biological response after two cycles. Five cycles were given. There was only one episode of febrile neutropenia. We collected 3.39 × 10 4 CFU-GM/kg by cytapheresis after the fifth cycle and G-CSF stimulation. High-dose chemotherapy (HDC) included busulfan 4 mg/kg p.o. daily on days 1 to 4 and thiotepa 300 mg/m 2 daily i.v. on days 5 to 8, followed by infusion of autologous peripheral hematopoietic stem cells. Neutropenia (less than 0.5 × 10 9 /l) and thrombopenia (less than 50 × 10 9 /l) lasted 11 days and 14 days respectively. Grade 4 mucositis necessitated morphine hydrochloride (30 mg/day) and parenteral nutrition for 7 days. The patient left the hospital 20 days after the stem cell transplant. Tumor response was assessed by spinal and cerebral magnetic resonance imaging, bone marrow aspiration and complete blood count. The patient is still in complete response 6 months after HDC.
As did Millot et al, we treated our patient on the basis of a pediatric schedule. 2 Indeed, adult medulloblastoma has an outcome and prognostic factors similar to those seen in children. 3 We confirm the tolerability and efficiency of this
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Although the treatment of primary medulloblastoma includes surgical excision and post-surgical irradiation, there is no established treatment for metastatic recurrence. The case described by Foa et al confirms the acceptable toxicity of etoposide and carboplatin followed by high-dose chemotherapy (HDC) with hematopoietic stem cell transplantation in young adults with bone marrow relapse of medulloblastoma. Our two cases and this present case emphasize the fact that medulloblastoma is a chemoprotocol. Treatments for recurrent medulloblastoma have not been randomized or uniform, although treatment of extraneural metastatic medulloblastoma is mainly based on chemotherapy. Since 1980, studies of patients with recurrent disease have permitted identification of a number of active new drugs or drug combinations. 4, 5 The data from several published trials using high-dose chemotherapy have been promising, 6 but no consensus has been reached. As do Millot et al, we believe that high-dose chemotherapy followed by hematopoietic stem cell transplantation in adult extraneuronal medulloblastoma relapse should be considered. therapy-sensitive tumor even in the recurrent metastatic situation. However, the effectiveness of such a treatment strategy must be determined in a larger number of patients with extended follow-up (unfortunately, central nervous system relapse occurred 21 months after HDC in one of our two patients). 
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